NEW HAVEN, Conn., March 27, 2019 (GLOBE NEWSWIRE) -- Specialty diagnostics company Precipio, Inc. (NASDAQ: PRPO) today announced that it has received the expected delisting determination from
Nasdaq Staff. The Company has subsequently filed a request for a hearing before the Nasdaq Hearings Panel (the "Panel"), as
management believes that it has strong basis for requesting the appeal. The process involves the Company requesting a compliance
hearing within 7 days from the receipt of the delisting notification. Companies are typically scheduled for a hearing 30 to 45 days
from the date of its request for a hearing, and the Hearing Panel typically issues a decision within 30 days of the hearing.
As informed by Nasdaq, the delisting of the company will be postponed pending a decision by the Hearing Panel -
meaning the company shall remain listed on Nasdaq until the hearing takes place, and the Hearing Panel has issued a written
decision.
About Precipio
Precipio has built a platform designed to eradicate the problem of misdiagnosis by harnessing the intellect, expertise and
technology developed within academic institutions and delivering quality diagnostic information to physicians and their patients
worldwide. Through its collaborations with world-class academic institutions specializing in cancer research, diagnostics and
treatment such as the Yale School of Medicine and Harvard’s Dana-Farber Cancer Institute, Precipio offers a new standard of
diagnostic accuracy enabling the highest level of patient care. For more information, please visit www.precipiodx.com.
Forward-Looking Statements
Certain statements in this press release constitute “forward-looking statements,” within the meaning of federal securities laws,
including potential market opportunity, plans and prospects and other statements containing the words “anticipate,” “intend,”
“may,” “plan,” “predict,” “will,” “would,” “could,” “should,” and similar expressions, constitute forward-looking statements within
the meaning of The Private Securities Litigation Reform Act of 1995. The Company's actual results could differ materially from
those anticipated in these forward-looking statements as a result of various factors. Factors that could cause future results to
materially differ from the recent results or those projected in forward-looking statements include the known risks, uncertainties
and other factors described in the Company’s definitive proxy statement filed on May 29, 2018, the Company’s Quarterly Report on
Form 10-Q for the quarter ended September 30, 2018 and on the Annual Report on Form 10-K for the year ended December 31, 2017 as
well as the Company’s prior filings and from time to time in the Company’s subsequent filings with the Securities and Exchange
Commission. Any change in such factors, risks and uncertainties may cause the actual results, events and performance to differ
materially from those referred to in such statements. All information in this press release is as of the date of the release and
the Company does not undertake any duty to update this information, including any forward-looking statements, unless required by
law.
Precipio Inquiries: investors@precipiodx.com +1-203-787-7888
